REG - RTW Biotech Opp. - Update on Kailera Therapeutics

RTW Biotech OpportunitiesAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250717:nRSQ3853Ra&default-theme=true

RNS Number : 3853R  RTW Biotech Opportunities Ltd  17 July 2025

LEI: 549300Q7EXQQH6KF7Z84

17 July 2025

RTW Biotech Opportunities Ltd

Update on Kailera Therapeutics

 

RTW Biotech Opportunities Ltd (the "Company"), the London Stock
Exchange-listed investment company focused on identifying transformative
assets with high growth potential across the life sciences sector, notes the
recent announcement from private portfolio company Kailera Therapeutics
("Kailera").

 

Kailera is a clinical-stage biopharmaceutical company advancing a broad
pipeline of next-generation therapies for the treatment of obesity. Its lead
product candidate, KAI-9531 (HRS9531 in China), is a novel dual GLP-1/GIP
receptor agonist administered via once-weekly subcutaneous injection. As at 30
June, Kailera represented 5.0% of NAV.

 

On 15 July, Kailera and its partner, Hengrui Pharma, announced positive
topline data from the China Phase 3 clinical trial of HRS9531 in individuals
living with obesity or overweight. The trial met both primary endpoints,
demonstrating superior weight loss and a greater percentage of participants
achieving at least 5% body weight reduction compared to placebo. The safety
profile was favourable and consistent with other GLP-1-based treatments, with
most treatment-emergent adverse events being mild to moderate and
gastrointestinal-related.

 

Hengrui Pharma plans to submit a New Drug Application (NDA) for chronic weight
management in China. Kailera is advancing KAI-9531 to global clinical trials.

 

Kailera's announcement can be found here
(https://www.kailera.com/press-release/hengrui-pharma-and-kailera-therapeutics-report-positive-topline-data-from-phase-3-obesity-trial-in-china-of-dual-glp-1-gip-receptor-agonist-hrs9531/)
.

 

Rod Wong, CIO of RTW Investments, said, "We are excited to see the results of
Kailera's lead product, KAI9531, in the China Phase 3 obesity study, which
marks a significant milestone in its development. The strong efficacy and
favourable safety profile observed in the Chinese population underscore its
potential to become a transformative treatment for millions of people living
with obesity and related cardiometabolic conditions. With the prevalence of
obesity continuing to rise, we believe Kailera is well positioned to bring
this product to global markets. Together with Corxel's once-daily oral GLP-1
drug candidate, our portfolio reflects a strategic commitment to delivering
both injectable and oral solutions that can meet diverse patient needs and
reshape the future of obesity care."

 

Enquiries:

 RTW Investments, LP - Investment Manager  +44 (0)20 7959 6362

 Oliver Kenyon                             biotechopportunities@rtwfunds.com

 Woody Stileman

 Krisha McCune (Investor Relations)

 Cadarn Capital - PR & IR Partner

 Lucy Clark (PR)                           +44 (0)7984 184 461 / lucy@cadarncapital.com

 David Harris (Distribution)               +44 (0)7368 883 211 / david@cadarncapital.com

 Deutsche Numis - Joint Corporate Broker   +44 (0)20 7260 1000

 Freddie Barnfield

 Nathan Brown

 BofA Securities - Joint Corporate Broker  +44 (0)20 7628 1000

 Edward Peel

 Alex Penney

 Altum (Guernsey) Limited                  +44 (0)1481 703 100

 Joanna Duquemin Nicolle

 Sadie Morrison

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

***********

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDBRGDRSUBDGUL